Liver Cancer Disparities in Alaska Native and American Indian People
阿拉斯加原住民和美洲印第安人的肝癌差异
基本信息
- 批准号:10286757
- 负责人:
- 金额:$ 101.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-06 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Air PollutantsAlaska NativeAmerican IndiansBiological MarkersBiometryBiostatistics CoreCancer BiologyCancer EtiologyCarcinogensCessation of lifeChadCharacteristicsChemopreventionCherokee IndianCirrhosisClinicalClinical ResearchCollaborationsColorectal CancerContinuity of Patient CareDevelopmentDiabetes MellitusEarly DiagnosisEffectivenessEpidemiologyEpigenetic ProcessExposure toFaceFunctional disorderGeneticHBV GenotypeHealth ServicesHealth systemHepatitis BHepatitis CHepatologyHigh PrevalenceIncidenceInternationalLiverLiver diseasesLongitudinal cohortMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of liverMalignant neoplasm of lungMalignant neoplasm of prostateModelingMutationNative-BornObesityOutcomeParticulate MatterPathologyPatientsPerformancePersonsPrevalencePrimary carcinoma of the liver cellsPrognosisProtocols documentationRadiology SpecialtyRecurrenceResearchRiskRisk FactorsRoleTestingTimeUnited StatesViral hepatitisWomanalcohol use disorderbasebiobankbiomarker developmentbiomarker panelcancer geneticscancer health disparitychronic liver diseasedata repositorydisparity eliminationfine particleshigh riskimprovedinnovationmalignant breast neoplasmmenmortalitymultidisciplinarynon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel markerprogramsprospectiverisk stratificationscreeningsurveillance strategytranslational approachtreatment responsetribal health
项目摘要
ABSTRACT: OVERALL COMPONENT - LIVER CANCER DISPARITIES IN AI/AN
HCC is the fastest-rising major malignancy in the United States. While deaths related to lung, breast, prostate
and colorectal cancer have declined dramatically by 40-53% between 1990 and 2016, HCC is the only major
malignancy whose mortality is rising in both men and women and has had the highest average annual
percentage change2. HCC is now the 6th leading cause of cancer-related death in the U.S. It is projected to
surpass breast and colorectal cancer to become the 3rd leading cause of cancer-related death by 2030.
American Indian/Alaska Native (AI/AN) people face a disproportionally high burden of HCC. AI/AN people have
2.4 times higher HCC incidence and 2.5 times higher HCC-related mortality than white persons. AI/AN people
have a very high incidence and prevalence of conditions that cause HCC such as viral hepatitis C and B, alcohol
use disorders, NAFLD/NASH, obesity and diabetes. Additionally, AI/AN patients have unique risk factors and
pathogenetic mechanisms for HCC development, such as high prevalence of infection with HBV genotype F1b,
unique mutations in the core region of HBV genotype F1b and high exposure to air pollutants (particulate matter
<2.5µm or “PM2.5”), which are recognized carcinogens.
The main focus of our Liver Cancer in AI/AN Disparities (Li-CAD) P20 program is to eliminate disparities in
EARLY DETECTION. We believe that the most critical disparities and deficiencies in HCC management, and
the greatest opportunities for improvement, lie in early detection. The overarching aim of this P20 Program is
to apply novel, innovative, translational approaches to surveillance and early detection of HCC that are informed
by unique aspects of HCC pathophysiology and epidemiology in AI/AN people in order to eliminate disparities,
improve early detection and ultimately reduce HCC-related mortality. The overarching strategy is to introduce
“Precision HCC Screening” based on HCC risk stratification and risk-based surveillance
The P20 Li-CAD program will achieve the following AIMS:
1. PROJECT 1. Transform biomarker-based surveillance for early detection of HCC in medium and low-risk
AI/AN patients. We will test and adapt exciting biomarker panels in AI/AN patients and develop innovative
longitudinal (Bayesian) biomarker modeling strategies to maximize the performance characteristics of biomarker-
based surveillance.
2. PROJECT 2. Develop novel risk stratification strategies and test abbreviated MRI-based surveillance for early
detection of HCC in high-risk AI/AN patients. We will elucidate the role of HBV genotype-specific mutations in
HCC; develop AI/AN-specific “HCC Risk Calculators” for HCC risk stratification and risk-based surveillance; and
use these HCC Risk Calculators to identify high-risk patients for more intensive HCC surveillance strategies
utilizing novel abbreviated MRI protocols, which will be tested in a small pilot and feasibility RCT
摘要:总体组成部分 - AI/AN 中的肝癌差异
HCC 是美国增长最快的主要恶性肿瘤。而死亡与肺、乳腺、前列腺有关
1990 年至 2016 年间,结直肠癌急剧下降 40-53%,HCC 是唯一的主要癌症
男性和女性死亡率均呈上升趋势且年平均死亡率最高的恶性肿瘤
百分比变化2。 HCC 目前是美国癌症相关死亡的第六大原因。预计
到2030年,癌症将超过乳腺癌和结直肠癌,成为癌症相关死亡的第三大原因。
美洲印第安人/阿拉斯加原住民 (AI/AN) 面临着不成比例的高肝癌负担。 AI/AN 人有
与白人相比,HCC 发病率高 2.4 倍,HCC 相关死亡率高 2.5 倍。人工智能/人工智能人
导致 HCC 的疾病的发病率和患病率非常高,例如丙型和乙型病毒性肝炎、酒精
使用障碍、NAFLD/NASH、肥胖和糖尿病。此外,AI/AN 患者具有独特的危险因素
HCC 发展的发病机制,例如 F1b 基因型 HBV 感染的高患病率,
HBV 基因型 F1b 核心区域的独特突变以及空气污染物(颗粒物)的高暴露
<2.5μm 或“PM2.5”),这是公认的致癌物质。
我们的肝癌 AI/AN 差异 (Li-CAD) P20 计划的主要重点是消除
早期发现。我们认为 HCC 管理中最关键的差异和缺陷,以及
最大的改进机会在于早期发现。 P20 计划的总体目标是
应用新颖、创新、转化的方法来监测和早期发现 HCC
通过 AI/AN 人群 HCC 病理生理学和流行病学的独特方面,以消除差异,
改善早期发现并最终降低 HCC 相关死亡率。总体战略是引入
基于HCC风险分层和风险监测的“精准HCC筛查”
P20 Li-CAD 计划将实现以下目标:
1. 项目 1. 转变基于生物标志物的监测,以早期发现中低风险的 HCC
AI/AN 患者。我们将在 AI/AN 患者中测试和调整令人兴奋的生物标志物组,并开发创新的
纵向(贝叶斯)生物标志物建模策略,以最大化生物标志物的性能特征
为基础的监视。
2. 项目 2. 制定新的风险分层策略并测试基于 MRI 的早期监测
高危 AI/AN 患者中 HCC 的检测。我们将阐明 HBV 基因型特异性突变在
肝癌;开发 AI/AN 专用的“HCC 风险计算器”,用于 HCC 风险分层和基于风险的监测;和
使用这些 HCC 风险计算器来识别高风险患者,以实施更强化的 HCC 监测策略
利用新颖的简化 MRI 协议,该协议将在小型试点和可行性 RCT 中进行测试
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Mallory Grady其他文献
CPG island methylator phenotype and patients with multiple colorectal cancers
- DOI:
10.1016/s0016-5085(00)82254-4 - 发表时间:
2000-04-01 - 期刊:
- 影响因子:
- 作者:
William Mallory Grady;Sanford Markowitz;Joseph Willis - 通讯作者:
Joseph Willis
William Mallory Grady的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William Mallory Grady', 18)}}的其他基金
Administrative Core-Biomarkers for optimizing risk prediction and early detection of cancers of the colon and esophagus
用于优化结肠癌和食道癌风险预测和早期检测的管理核心生物标志物
- 批准号:
10677826 - 财政年份:2022
- 资助金额:
$ 101.15万 - 项目类别:
Comprehensive atlas of advanced adenomas and their surrounding primed colon: A multi-omics evaluation and clinical impact assessment
晚期腺瘤及其周围的结肠的综合图谱:多组学评估和临床影响评估
- 批准号:
10707100 - 财政年份:2022
- 资助金额:
$ 101.15万 - 项目类别:
Biomarkers for optimizing risk prediction and early detection of cancers of the colon and esophagus
用于优化结肠癌和食道癌风险预测和早期检测的生物标志物
- 批准号:
10677825 - 财政年份:2022
- 资助金额:
$ 101.15万 - 项目类别:
Comprehensive atlas of advanced adenomas and their surrounding primed colon: A multi-omics evaluation and clinical impact assessment
晚期腺瘤及其周围的结肠的综合图谱:多组学评估和临床影响评估
- 批准号:
10920978 - 财政年份:2022
- 资助金额:
$ 101.15万 - 项目类别:
Comprehensive atlas of advanced adenomas and their surrounding primed colon: A multi-omics evaluation and clinical impact assessment
晚期腺瘤及其周围的结肠的综合图谱:多组学评估和临床影响评估
- 批准号:
10519074 - 财政年份:2022
- 资助金额:
$ 101.15万 - 项目类别:
The intestinal microbiome contribution to colon cancer and senescence
肠道微生物组对结肠癌和衰老的贡献
- 批准号:
10831334 - 财政年份:2021
- 资助金额:
$ 101.15万 - 项目类别:
The role of the senescent microenvironment on cancer initiating cells in the colon.
衰老微环境对结肠癌起始细胞的作用。
- 批准号:
10638374 - 财政年份:2021
- 资助金额:
$ 101.15万 - 项目类别:
相似海外基金
NNA Research: Collaborative Research: Towards resilient water infrastructure in Alaska Native communities through knowledge co-production
NNA 研究:合作研究:通过知识共同生产为阿拉斯加原住民社区打造具有复原力的水基础设施
- 批准号:
2220518 - 财政年份:2023
- 资助金额:
$ 101.15万 - 项目类别:
Standard Grant
NNA Research: Collaborative Research: Towards resilient water infrastructure in Alaska Native communities through knowledge co-production
NNA 研究:合作研究:通过知识共同生产为阿拉斯加原住民社区打造具有复原力的水基础设施
- 批准号:
2220516 - 财政年份:2023
- 资助金额:
$ 101.15万 - 项目类别:
Standard Grant
NNA Research: Collaborative Research: Towards resilient water infrastructure in Alaska Native communities through knowledge co-production
NNA 研究:合作研究:通过知识共同生产为阿拉斯加原住民社区打造具有复原力的水基础设施
- 批准号:
2220517 - 财政年份:2023
- 资助金额:
$ 101.15万 - 项目类别:
Standard Grant
Deep molecular and cellular profiling of colorectal cancer tumor and immune microenvironment in Alaska Native people
阿拉斯加原住民结直肠癌肿瘤和免疫微环境的深入分子和细胞分析
- 批准号:
10651205 - 财政年份:2023
- 资助金额:
$ 101.15万 - 项目类别:
Development of an Instrument for Assessment of Indigenous Historical Trauma as a Social Determinant of Health Among American Indian/Alaska Native Populations
开发一种评估土著历史创伤作为美洲印第安人/阿拉斯加原住民健康社会决定因素的工具
- 批准号:
10736011 - 财政年份:2023
- 资助金额:
$ 101.15万 - 项目类别:
Understanding cancer and comorbidities among American Indian and Alaska Native people
了解美洲印第安人和阿拉斯加原住民的癌症和合并症
- 批准号:
10722119 - 财政年份:2023
- 资助金额:
$ 101.15万 - 项目类别:
Urban American Indian/Alaska Native Cultural Eating Values and Behaviors: Community-based, mixed methods research to inform a holistic and culturally-informed diabetes prevention intervention program
城市美洲印第安人/阿拉斯加原住民文化饮食价值观和行为:基于社区的混合方法研究,为全面且文化丰富的糖尿病预防干预计划提供信息
- 批准号:
10679529 - 财政年份:2023
- 资助金额:
$ 101.15万 - 项目类别:
Planning Grant: Moving Forward Together - Transforming Arctic Geosciences for Alaska Native Sovereignty and Science
规划拨款:共同前进 - 为阿拉斯加原住民主权和科学转变北极地球科学
- 批准号:
2228064 - 财政年份:2023
- 资助金额:
$ 101.15万 - 项目类别:
Standard Grant
Alaska Native Communities Advancing Vaccine Uptake
阿拉斯加原住民社区促进疫苗接种
- 批准号:
10504537 - 财政年份:2022
- 资助金额:
$ 101.15万 - 项目类别:
Alaska Native Family-Based, Financial Incentives Intervention for Smoking Cessation: an RCT
基于阿拉斯加原住民家庭的戒烟经济激励干预措施:随机对照试验
- 批准号:
10612408 - 财政年份:2022
- 资助金额:
$ 101.15万 - 项目类别:














{{item.name}}会员




